Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts

Aims The relevance of lipoprotein(a) [Lp(a)] concentrations and low-molecular-weight (LMW) apo(a) phenotypes in peripheral arterial disease (PAD) has only been investigated by few studies. Therefore, we analysed this association in three independent cohorts and performed a Mendelian Randomization approach using instrumental variable regression. Methods and results Lp(a) concentrations, apo(a) phenotypes, and one SNP in the LPA gene (rs10455872) were measured in the CAVASIC study, including 241 male patients with intermittent claudication and 246 age- and diabetes-matched controls as well as in the two population-based studies KORA F3 (n = 3184) and KORA F4 (n = 3080). In KORA F3/F4, 109/80 persons suffered from intermittent claudication, 200/144 from PAD, and 128/103 showed an ankle–brachial index (ABI) <0.9. In CAVASIC, adjusted logistic regression analyses revealed significant associations between an increase of log-Lp(a) per one standard deviation (SD) (OR = 1.28, P = 0.02) as well as LMW apo(a) phenotypes and symptomatic PAD (OR = 1.65, P = 0.03). Linear regression models with continuous ABI showed a significant association in the combined analyses of KORA F3/F4: an increase in log-Lp(a) per one SD (β = −0.006, P = 0.005) and the presence of LMW apo(a) phenotypes (β = −0.011, P = 0.02) or the minor allele of rs10455872 (ß = −0.016, P = 0.03) were associated with a decrease in ABI in the fully adjusted linear and instrumental variable regression models. Conclusion Analyses in three independent populations showed significant associations of Lp(a) concentrations, LMW apo(a) phenotypes, and rs10455872 with PAD. This points to a causal relationship between Lp(a) and PAD since the genetically determined apo(a) phenotypes and SNP alleles are indeed associated with PAD.

[1]  F. Kronenberg.  Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better , 2014, Journal of internal medicine.

[2]  F. Kronenberg.  Lipoprotein(a): there's life in the old dog yet. , 2014, Circulation.

[3]  B. Nordestgaard,et al.  Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. , 2013, The lancet. Diabetes & endocrinology.

[4]  M. M. Joosten,et al.  Oxidation-specific biomarkers and risk of peripheral artery disease. , 2013, Journal of the American College of Cardiology.

[5]  F. Kronenberg,et al.  Reproductive factors and its association with peripheral arterial disease in women aged 52-81 years: the KORA F4 study. , 2013, Atherosclerosis.

[6]  I. Kullo,et al.  Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease. , 2013, American journal of hypertension.

[7]  F. Kronenberg,et al.  Comparison and evaluation of cardiac biomarkers in patients with intermittent claudication: results from the CAVASIC study. , 2013, Clinical chemistry.

[8]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[9]  D. Gurdasani,et al.  Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease: The EPIC-Norfolk Prospective Population Study , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Tsao,et al.  Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. , 2012, Journal of the American College of Cardiology.

[11]  R. Collins,et al.  Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease but Not With Stroke Risk in the Heart Protection Study , 2011, Circulation. Cardiovascular genetics.

[12]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[13]  S. Bandinelli,et al.  Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). , 2010, The American journal of cardiology.

[14]  J. Danesh,et al.  Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. , 2010, Journal of the American College of Cardiology.

[15]  David M. Evans,et al.  Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. , 2010, Atherosclerosis.

[16]  Harald Darius,et al.  Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease , 2009, Circulation.

[17]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[18]  L. Ferrucci,et al.  Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study). , 2009, Journal of the American College of Cardiology.

[19]  Florian Kronenberg,et al.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: A systematic in-depth review , 2009, Experimental Gerontology.

[20]  F. Kronenberg,et al.  Intermittent claudication in the Erfurt Male Cohort (ERFORT) Study: its determinants and the impact on mortality. A population-based prospective cohort study with 30 years of follow-up. , 2008, Atherosclerosis.

[21]  F. Kronenberg,et al.  Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. , 2008, Clinical chemistry.

[22]  N. Cook,et al.  Symptomatic Peripheral Arterial Disease in Women: Nontraditional Biomarkers of Elevated Risk , 2008, Circulation.

[23]  E. Emanuele,et al.  The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[24]  B. Toursarkissian.  Commentary: risk factors for progression of peripheral arterial disease in large and small vessels. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Circulation. 2006;113:2623-2629. , 2007, Perspectives in vascular surgery and endovascular therapy.

[25]  F. Kronenberg,et al.  Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. , 2007, Clinical chemistry.

[26]  Y. Ostchega,et al.  Prevalence of Peripheral Arterial Disease and Risk Factors in Persons Aged 60 and Older: Data from the National Health and Nutrition Examination Survey 1999–2004 , 2007, Journal of the American Geriatrics Society.

[27]  N. Shammas,et al.  Epidemiology, classification, and modifiable risk factors of peripheral arterial disease , 2007, Vascular health and risk management.

[28]  G. Lowe,et al.  Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. , 2007, European heart journal.

[29]  F. Kronenberg,et al.  Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. , 2006, European heart journal.

[30]  P. Ridker,et al.  Risk Factors for Progression of Peripheral Arterial Disease in Large and Small Vessels , 2006, Circulation.

[31]  Elizabeth Selvin,et al.  Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000 , 2004, Circulation.

[32]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[33]  F. Kronenberg,et al.  Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[34]  F. Kronenberg,et al.  Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[35]  Paul H. C. Eilers,et al.  Flexible smoothing with B-splines and penalties , 1996 .

[36]  F. Kronenberg,et al.  Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. , 1994, Journal of lipid research.

[37]  M. Sentí,et al.  Apolipoprotein(a) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheral vascular disease. , 1993, Atherosclerosis.

[38]  E. Boerwinkle,et al.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[39]  O. Faergeman,et al.  Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[40]  G. Utermann,et al.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.